Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
US FDA Accepts Myovant’s Relugolix Triple Combo for Review in Uterine Fibroids
Myovant Sciences, a subsidiary of Sumitomo Dainippon Pharma, said on August 17 that the US FDA has accepted its new drug application (NDA) for relugolix triple combination tablet (relugolix + estradiol + norethindrone) for the treatment of women with heavy…
To read the full story
Related Article
BUSINESS
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026





